| Updated in 11/7/2019 10:25:34 AM |
Viewed: 389 times |
(Journal Article) |
Journal of the National Comprehensive Cancer Network : JNCCN 13 (5): 515-24 (2015)
Non-Small Cell Lung Cancer, Version 6.2015.
David S Ettinger
,
Douglas E Wood
,
Wallace Akerley
,
Lyudmila A Bazhenova
,
Hossein Borghaei
,
David Ross Camidge
,
Richard T Cheney
,
Lucian R Chirieac
,
Thomas A D'Amico
,
Todd L Demmy
,
Thomas J Dilling
,
M Chris Dobelbower
,
Ramaswamy Govindan
,
Frederic W Grannis
,
Leora Horn
,
Thierry M Jahan
,
Ritsuko Komaki
,
Lee M Krug
,
Rudy P Lackner
,
Michael Lanuti
,
Rogerio Lilenbaum
,
Jules Lin
,
Billy W Loo
,
Renato Martins
,
Gregory A Otterson
,
Jyoti D Patel
,
Katherine M Pisters
,
Karen Reckamp
,
Gregory J Riely
,
Eric Rohren
,
Steven E Schild
,
Theresa A Shapiro
,
Scott J Swanson
,
Kurt Tauer
,
Stephen C Yang
,
Kristina Gregory
,
Miranda Hughes
,
National comprehensive cancer network
ABSTRACT
These NCCN Guidelines Insights focus on recent updates to the 2015 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC). Appropriate targeted therapy is very effective in patients with advanced NSCLC who have specific genetic alterations. Therefore, it is important to test tumor tissue from patients with advanced NSCLC to determine whether they have genetic alterations that make them candidates for specific targeted therapies. These NCCN Guidelines Insights describe the different testing methods currently available for determining whether patients have genetic alterations in the 2 most commonly actionable genetic alterations, notably anaplastic lymphoma kinase (ALK) gene rearrangements and sensitizing epidermal growth factor receptor (EGFR) mutations.